Prevention & lipidsResearch article
Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease
- Modelling study
- literature review
- simulation using the SMART-REACH survival model
- 7 European countries
Authors' conclusion
This is a step in better quantifying the impact of improved secondary ASCVD prevention, giving an indication of the potential of EU and national cardiovascular health plans in cardiovascular survival gains.
Study context
- Population
- Patients with established Atherosclerotic Cardiovascular Disease (ASCVD) in Denmark, France, Germany, Italy, Poland, Spain and the UK7 countries
- Comparison
- Improved treatment coverage and smoking cessation vs current
- Outcome
- CV-event-free life-years gained by optimised secondary prevention:
- Hypertension
- Hypercholesterolaemia
- DM
- Tobacco smoking
Main finding
As reported in the abstract
CV-event-free life-years gained/year
- Across 7 countries (over)
- 94 359
- Germany
- 25 333
- Italy
- 21 144
- France
- 14 584
- UK
- 13 324
- Spain
- 9393
- Poland
- 9369
- Denmark
- 1212
Original publication
Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease. Eur J Prev Cardiol. Published 13 January 2026. doi:10.1093/eurjpc/zwag027
Summarised from the published abstract; every number is checked against it